树突状细胞的靶向抗肿瘤治疗进展  

Advances in targeted anti-cancer therapy of dendritic cells

作　　者：任远[1] 张锡林[2] 

机构地区：[1]第三军医大学学员旅四队 [2]第三军医大学基础部病原微生物学教研室,重庆400038

出　　处：《现代生物医学进展》2010年第17期3391-3393,共3页Progress in Modern Biomedicine

基　　金：重庆市重大科技专项基金CSTC;2007AB5029

摘　　要：树突状细胞(dendritic cell,DC)是目前已知体内最强的抗原提呈细胞(APC),其在肿瘤免疫中具有重要的作用。DC的靶向抗肿瘤治疗成为当今肿瘤免疫治疗的研究热点。本文就DC的抗肿瘤机制、DC基因修饰策略及DC疫苗的临床治疗进展进行综述。Dendritic cell （DC） which plays an important role in tumor immunity has been known as the most potent antigen-presenting cells in vivo. DC targeted anti-tumor therapy becomes the focus of current tumor immunotherapy. In this paper, the anti-tumor mechanism of DC, DC gene modification strategy and the clinical treatment of DC vaccine are reviewed.

关 键 词：树突状细胞 基因修饰 DC疫苗 靶向治疗 抗肿瘤免疫 

分 类 号：R730.5[医药卫生—肿瘤]